科济药业-B今日盘中股价大跌5.56%,引起市场广泛关注。从最新财报数据来看,该公司最近业绩出现大幅下滑,这可能是导致股价大跌的主要原因。
据报道,科济药业最新季报显示,公司实现营业收入694.66万港元,同比下滑逾60%;净利润则亏损3.85亿港元,上年同期为盈利;每股收益为-0.69港元,远低于上年同期水平。业绩大幅下滑主要源于公司主打产品疫情期间销售不佳。
值得一提的是,尽管业绩出现大幅下滑,但机构对该股前景依旧看好。有一半券商给予"买入"评级,另一半给予"持有"评级。这或许与公司新药研发进展顺利有关。总的来说,公司当前阶段经营状况并不乐观,未来能否重新走上正轨,还有待时日观察。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.